Asceneuron SA
Biotechnology ResearchView the employees at
Asceneuron SA-
Dirk Beher Experienced biotech executive (CEO/CSO roles), board member, drug hunter & entrepreneur
-
Lausanne Metropolitan Area
-
Top 10%
Astrid Sand Senior Scientist, Asceneuron SA-
Lausanne, Vaud, Switzerland
-
Rising Star
Sandra MILLET Change Management / Communication-
Top 5%
Ryan S. SVP at Asceneuron-
San Francisco, California, United States
-
Rising Star
Sandra MILLET Communication & Change Management Specialist-
Geneva, Geneva, Switzerland
-
Rising Star
Overview
Asceneuron is a clinical stage biotech company focused on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical need. The pipeline reflects our ambition to develop treatments for a wide a range of neurodegenerative diseases including orphan tauopathies, Alzheimer’s and Parkinson’s disease. Asceneuron has two clinical stage small molecule O-GlcNAcase inhibitors in development for the treatment of proteinopathies including Parkinson’s Disease, Alzheimer’s disease and related disorders. Asceneuron is a privately held company financed by a renowned syndicate of investors consisting of Sofinnova Partners, M Ventures, SR One, Johnson & Johnson Innovation – JJDC, Inc. (JJDC) and Kurma Partners. For more information, please visit www.asceneuron.com. Further information: www.asceneuron.com
-